Article
Iguratimod Attenuates Diabetic Cognitive Impairment via Suppressing B Cell Activation and CD8+ T Cell Cytotoxicity
2025-06-27
Abstract excerpt
<h4>Background: </h4> and Purpose Diabetes-induced cognitive impairment (DCI) is a common complication in diabetic patients with an unclear pathogenesis, and there are currently no approved therapeutic drugs available. Iguratimod (IGU) is a novel small molecule immunosuppressant used to treat rheumatoid arthritis. Given the emerging evidence revealing that immune responses mediate cognitive impairment, our study i...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d8c0fd60-a429-5d51-bb8e-aa75cf00e610
- DOI
- 10.22541/au.175102422.26432301/v1
